Osteonecrosis in the jaws of patients who are using oral biphosphonates to treat osteoporosis.
Dello Russo
Nicholas M
NM
Jeffcoat
Marjorie K
MK
Marx
Robert E
RE
Fugazzotto
Paul
P
D000284:Administration, Oral; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D024042:Collagen Type I / Q000097:blood; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D007275:Injections, Intravenous; D007571:Jaw Diseases / Q000139:chemically induced* / Q000517:prevention & control; D010010:Osteoclasts / Q000187:drug effects; D010020:Osteonecrosis / Q000139:chemically induced* / Q000517:prevention & control; D010024:Osteoporosis / Q000188:drug therapy*; D010455:Peptides / Q000097:blood; D012449:Safety
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide